Eplerenone Reduces Mortality Risk in Mild Heart Failure Patients

 

November 17, 2010

Eplerenone (Inspra) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone. The drug, by Pfizer, was compared to placebo and standard therapy in heart failure patients with mild symptoms in the EMPHASIS-HF trial.

The trial demonstrated a significant reduction in risk of cardiovascular death or heart failure hospitalizations.

In the trial, there was a higher incidence of hyperkalemia (elevated potassium) among patients assigned to eplerenone compared to placebo. However, hypokalemia (low potassium) was lower in the eplerenone group.

For more information: www.pfizer.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.